Xalud Therapeutics develops a non-viral plasmid DNA gene therapy platform that harnesses interleukin-10 (IL-10) to modulate immune responses and treat pathologic inflammation. Its lead candidate, XT-150, is a locally injectable plasmid DNA therapy expressing IL-10v, a proprietary long-acting modified IL-10 with enhanced durability. XT-150 is being evaluated in a Phase 2b study for moderate-to-severe osteoarthritis knee pain and a Phase 1/2a study for peripheral neuropathic pain; a study for facet joint syndrome is expected to be initiated by year-end. The company says these studies will serve as milestones toward potential approvals and will generate safety and efficacy data to guide future development. Additional indications are currently in the IND-enabling stage. Xalud announced an oversubscribed $30 million Series C to advance XT-150 through clinical development and expand its platform, and cited support from strategic advisors and investors.

Total raised

$30M

Funding rounds

1

Latest round

Series C

Latest activity

Aug 2021